Fundamental Applied Biology raises $21M

Fundamental Applied Biology raised $21 million in a series B round co-led by existing investor SV Life Sciences and new investor Alta Partners. Fundamental plans to develop its cell-free protein synthesis technology for biologic therapeutics and vaccines. The company's pipeline and disease focus are undisclosed. ...